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 Vitamin D deficiency is a recognized 
risk factor for increased mortality in the 
general population 1 and for the accelerated 
progression of renal and cardiovascular 
damage in kidney disease patients. 2 Th e 
kidney is essential for the vitamin D actions 
that increase survival, because renal prox-
imal tubular cells are the main site for the 
synthesis of circulating 1,25-dihydroxy-
vitamin D (calcitriol), the hormonal form 
of vitamin D responsible for endocrine 
vitamin D actions, and also because renal 
proximal tubular cells recycle 25-hydroxy-
vitamin D from the glomerular ultrafi ltrate 
back to the circulation, thereby helping 
maintain the serum levels of 25-hydroxy-
vitamin D required for extrarenal calcitriol 
production. 2 
 Th e activation of the vitamin D receptor 
(VDR), either by the circulating calcitriol 
produced mostly in the kidney, or by the 
calcitriol produced locally by numerous 
cell types other than renal proximal tubu-
lar cells, modulates the expression of genes 
that prevent or slow the development of 
secondary hyperparathyroidism, bone 
disease, and abnormalities in calcium and 
phosphate homeostasis that predispose 
to ectopic calcifications and renal and 
cardiovascular damage, thereby decreas-
ing morbidity and mortality rates. 2 
 Th e kidney is also a key target for the 
actions of the calcitriol / VDR complex that 
associate with renoprotection and 
improved survival in healthy individuals, 
and also in patients with kidney disease 
and experimental models of kidney dis-
ease. 2 Importantly, the key renal actions of 
the calcitriol / VDR complex extend beyond 
the induction of active transepithelial cal-
cium reabsorption in the distal nephron, 
the suppression of cyp27b1 (1  -hydroxy-
lase, the enzyme responsible for calcitriol 
synthesis), and the induction of cyp24a1 
(24-hydroxylase, the enzyme responsible 
for calcitriol degradation) in renal proxi-
mal tubular cells, all of which contribute to 
the tight control of the calcium / calcitriol / 
parathyroid hormone axis that maintains 
calcium homeostasis and skeletal integ-
rity. 3,4 Several genes are induced by the 
calcitriol / VDR complex to enhance renal 
calcium entry, including  TRPV5 , the rate-
limiting step for renal calcium uptake from 
the glomerular ultrafi ltrate;  klotho , a   -glu-
curonidase that entraps TRPV5 to the 
plasma membrane via the hydrolysis of 
extracellular sugar residues; the calbindins 
 D28k and  D9k , redundant in binding intra-
cellular calcium to protect the cells from 
excessive calcium accumulation; and also 
the sodium / calcium exchanger  NCX1 and 
the calcium pump  PMCA1b , involved 
in the basolateral extrusion of calcium. 4 
However, in recent years, the main focus in 
nephrology has switched from the exclu-
sive safe control of the calcium / calcitriol / 
parathyroid hormone axis to prevent and 
treat secondary hyperparathyroidism, 
to also include calcitriol / VDR control of 
a novel and complex endocrine axis that 
prevents or attenuates hyperphosphatemia 
and ectopic calcifi cations: calcitriol / VDR 
induction of fi broblast growth factor 23 
(FGF23), a bone-derived phosphatonin 
with potent phosphaturic eff ects, and renal 
klotho, a longevity gene and a coreceptor 
for phosphaturic responses to FGF23. 3 
Calcitriol / VDR induction of FGF23 and 
klotho may partially account for many of 
the health and longevity benefi ts of a nor-
mal vitamin D status. Indeed, inactivation 
of FGF23, or klotho in mice, results in pre-
mature aging, marked increases in vascular 
calcification and atherosclerosis, and 
decreased lifespan. In turn, FGF23 is 
the perfect calcitriol counterregulatory 
hormone, because it inhibits both renal 
phosphate reabsorption and calcitriol 
biosynthesis and also enhances cyp24a1 in 
the kidney to further reduce circulating 
calcitriol levels. Accordingly, the double 
knockout of FGF23 and either the VDR or 
cyp27b1 in mice essentially rescues the 
FGF23-null phenotype, indicating that the 
ability of FGF23 – klotho to function as a 
counterregulatory hormone to calcitriol is 
key to its health and longevity benefi ts. 3 
 In agreement with the importance of the 
renal calcitriol / VDR complex in the distal 
tubule to maintain both renal calcium reab-
sorption and the phosphate / calcitriol / 
FGF23 – klotho axis, the elegant study by 
Wang and colleagues 5 (this issue), which 
examines renal VDR content along the 
mouse nephron using a new highly specifi c 
and sensitive anti-VDR antibody, fi nds the 
highest VDR expression in distal tubules. 
Wang and colleagues also demonstrate 
a VDR content in proximal tubular cells 
24-fold lower than that in distal tubules. In 
proximal tubular cells, the calcitriol / VDR 
complex not only tightly controls calcitriol 
production through dual mechanisms, 
suppression of 1-hydroxylase and induc-
tion of 24-hydroxylase, but also induces 
the sodium-phosphate cotransporter 
NaPi2a, critical for the phosphaturic eff ects 
of FGF23. 3 Th e marked reduction in VDR 
content in the cells with the highest capac-
ity for calcitriol synthesis and local VDR 
 Renal vitamin D receptor 
expression and vitamin D 
renoprotection 
 Adriana S.  Dusso 1 
 Therapy to enhance the renoprotective actions of vitamin D receptor 
(VDR) activation should safely overcome the distinct VDR content along 
the nephron to effectively control renal calcium reabsorption, control 
renal klotho levels for the phosphaturic actions of FGF23, and inhibit 
proteinuria and the activation of the renin – angiotensin system. 
 Kidney International (2012)  81, 937 – 939.  doi: 10.1038/ki.2012.30 
 1 Division of Experimental Nephrology, Lleida 
Institute for Biomedical Research, Lleida School of 
Medicine, University of Lleida ,  Lleida ,  Spain 
 Correspondence: Adriana S. Dusso, Division 
of Experimental Nephrology, IRBLleida, 
Avenida Rovira Roure 80, 25198 Lleida, Spain. 
E-mail:  adusso@irblleida.cat 
see original article on page 993
commentar y
938   Kidney International (2012) 81 
activation may help maintain the integrity 
of the phosphate / calcitriol / FGF23 – klotho 
axis between bone and the kidney. Indeed, 
while the reduction in proximal tubule 
VDR content should decrease calcitriol 
induction of NaPi2a that could compro-
mise FGF23-driven phosphaturia, the tight 
control of renal calcitriol production will 
not be aff ected, as FGF23 synergizes with 
the calcitriol / VDR complex in the suppres-
sion of 1-hydroxylase and in the induction 
of 24-hydroxylase ( Figure 1 ). 
 An intriguing and translationally rele-
vant fi nding in the sound work by Wang 
and colleagues is that the VDR is barely 
detectable in podocytes, and undetectable 
in juxtaglomerular and mesangial cells. 5 
Th ese fi ndings pose an important challenge 
for therapy with VDR agonists to enhance 
vitamin D renoprotection in advanced 
chronic kidney disease through the inhibi-
tion or attenuation of proteinuria and of 
the activation of the renin – angio tensin sys-
tem (RAS), demonstrated in clinical trials 
and also in mouse and rat models of kidney 
disease. 6 Two strategies that especially 
interest nephrologists are the enhancement 
of endocrine and / or paracrine calcitriol /
 VDR actions involved in podocyte health 
and function, as a fi ltration barrier for the 
prevention of proteinuria, a well-recog-
nized hallmark of the progression of renal 
and cardiovascular damage; and, most 
critically, the direct suppression by 
calcitriol / VDR of the expression of the 
renin gene in juxtaglomerular cells, with 
the resulting inhibition of RAS activation 
and angiotensin II-driven infl ammatory, 
hypertensive, and oxidative damage to the 
renal parenchyma and the cardiovascular 
system. 7 Indeed, suppression of the expres-
sion of the renin gene by calcitriol suggests 
an advantage of VDR agonists over either 
angiotensin II-converting enzyme inhi-
bitors or angiotensin II type 1 receptor 
inhibitors, because their interruption of 
angiotensin II signaling promotes a feed-
forward loop for further increases in circu-
lating renin, resulting in intrarenal RAS 
activation. 6 Furthermore, a recent report 
extends our understanding of the renopro-
tective actions of the calcitriol / VDR com-
plex. The VDR agonist doxercalciferol 
prevents renal damage in a model of 
dietary-fat-induced renal disease, not 
only through the described reductions in 
proteinuria, podocyte injury, mesangial 
expansion, extracellular matrix protein 
accumulation, and RAS activation, but, 
more signifi cantly, through the attenuation 
of renal accumulation of neutral lipids by 
direct targeting of the enzymes that medi-
ate fatty acid and cholesterol synthesis. 8 
However, in light of the undetectable 
levels of VDR in juxtaglomerular cells and 
mesangial cells, as well as the low VDR 
content in podocytes, 5 and the multiple 
abnormalities in the induction and repres-
sion of gene expression by the calcitriol / 
VDR complex that are induced by chronic 
kidney disease 8 — namely, reduction of 
VDR heterodimerization with retinoid X 
receptor, defective binding to vitamin 
D-responsive sequences in the DNA of 
target genes, and abnormal recruitment of 
VDR co-regulators of gene expression — it 
becomes apparent from the work of Wang 
and collaborators 5 that the concentration 
of the VDR agonist required to compensate 
for the low VDR content to ensure appro-
priate VDR activation could reach levels 
high enough to compromise the health and 
longevity benefi ts of induction of klotho in 
renal distal tubules by calcitriol / VDR. 3 
 In summary, the work of Wang and 
colleagues assessing VDR content along 
the nephron 5 provides a sound reminder 
of the multiple levels of control of VDR 
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 Figure 1  |  Distinct VDR content and renoprotection. The markedly different VDR content along 
the nephron suggests that a distinct local VDR activation is responsible for vitamin D regulation of 
cell function in people with normal vitamin D status. Alb, albumin; 1,25D, 1,25-dihydroxyvitamin D 
or calcitriol; 25D, 25-hydroxyvitamin D; DCT, distal convoluted tubules; VDR, vitamin D receptor. 
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activation within the kidney and of the 
challenge ahead to obtain evidence-based 
recommendations for the safe and effi  ca-
cious implementation of renoprotective 
interventions with VDR agonists. 
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 Programmed anti-inflammatory 
macrophages protect against 
AKI and promote repair 
through trophic actions 
 Christof    Westenfelder 1  
 Because pharmacological interventions for the treatment of acute 
kidney injury (AKI) have remained ineffective, cell-based therapies have 
been developed. Marrow stromal cells have been found to be safe and 
potentially effective in study subjects. Jung  et al. demonstrate that 
macrophages made to overexpress anti-inflammatory interleukin-10 
protect rats with AKI through iron-mediated upregulation of lipocalin-2 
and its receptors, eliciting both anti-inflammatory and proliferative 
responses. These data further advance our understanding of cell-based 
therapies for AKI. 
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 For interventions to be effective in the 
prevention and treatment of ischemia / 
reperfusion- and nephrotoxin-induced 
acute kidney injury (AKI), they must 
simultaneously and sequentially target all 
involved pathomechanisms and repair 
mechanisms. Th is requires that anti-infl am-
matory and broad trophic actions be elicited 
in parallel. Anti-infl ammatory actions must 
reduce the complex cellular and molecular 
infl ammatory responses seen in the injured 
kidney and, optimally, those in remote 
organs. Unless this is accomplished, both 
the protection and the repair of the injured 
kidney through targeting of the micro-
vasculature, inhibition of apoptotic and 
necrotic loss of tubular and endothelial cells, 
and stimulation of repair through angio-
genic and mitogenic signals are diminished 
or absent. In other words, neither trophic 
actions of a given intervention nor anti-
infl ammatory actions  per se are generally 
suffi  cient to adequately protect renal func-
tion and to repair the damaged organ. Th is 
paradigm is illustrated in  Figure 1a . 
 Clinical trials with bioactive factors such 
as atrial natriuretic peptide, 1 insulin-like 
growth factor-I, 2 and erythropoietin 3 have 
been essentially ineff ective in patients with 
AKI, while being convincingly benefi cial 
in preclinical studies in otherwise healthy 
animals. Several factors in the clinical 
design of these trials may have contributed 
to these disappointing outcomes. Unlike 
experimental animals, study subjects suf-
fered from various comorbidities; treat-
ment was started at diff erent time points 
following the oft en-delayed diagnosis of 
AKI; and the tested factors are not able to 
adequately elicit both anti-infl ammatory 
and trophic responses. Because of the con-
tinued lack of eff ective drug-based thera-
pies for AKI, novel therapies more recently 
began to test cell-based approaches. Th e 
rationale for this approach lies in the fact 
that adult stem and progenitor cells, such 
as multipotent marrow stromal cells, also 
termed mesenchymal stem cells (MSC), 
endothelial progenitor cells, and, under 
certain circumstances, hematopoietic stem 
cells, have been shown to be renoprotec-
tive in experimental AKI — responses 
mediated by the ability of these cells to 
home to the injured kidney, to effect a 
robust anti-infl ammatory response com-
bined with antiapoptotic, angiogenic, and 
mitogenic actions. These promising 
preclinical data generated with MSC 
treatment protocols formed the basis, in 
our hands, for a phase 1 clinical trial 4 
(NCT00733876). On-pump cardiac sur-
gery patients (coronary artery bypass sur-
gery and / or valve surgery) received 
allogeneic MSCs in a dose escalation pro-
tocol. Th ey were at increased risk for post-
operative AKI due to underlying chronic 
kidney disease, diabetes mellitus, and, at 
age 65 or above, hypertension, congestive 
heart failure, and chronic obstructive 
pulmonary disease. Th e intervention was 
found to be safe, length of hospital stay 
and readmission rates were reduced, and 
at time of discharge none of the study sub-
jects met the Acute Kidney Injury Network 
